Thrombophilia as a multigenic disorder

Seminars in Thrombosis and Hemostasis

Volumn 24, Issue SUPPL. 1, 1998, Pages 13-20

  Miletich, Joseph P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antithrombin; Factor v; Inultigcnic disorder; Protein c; Thrombophilia; Thrombotic risk factor; Venous thrombosis

Indexed keywords

ANTITHROMBIN DEFICIENCY; DISEASE ASSOCIATION; GENE MUTATION; GENETIC LINKAGE; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; REVIEW; THROMBOPHILIA; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; FACTOR V; HUMANS; MUTATION; RISK FACTORS; THROMBOPHILIA;

EID: 0031788120     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Anderson FA, Jr, Wheeler B, Goldberg RJ, et al. A populationbased perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991;151:933-938
2. Briet E, Engesser L, Brommer EJP, Broekmans AW, Bertina RM. Thrombophilia: Its causes and a rough estimate of its prevalence. Thromb Haemostas 1987;58:39(Abst)
3. Egeberg O. Inherited antithrombin III deficiency causing thrombophilia. Thromb Diath Haemorrhag 1965; 13:516-530
4. Olds RJ, Lane DA, Mille B, Chowdhury V, Thein SL. Antithrombin: The principal inhibitor of thrombin. Semin Thromb Hemostas 1994:20:353-372
5. Lane DA, Olds RJ, Boisclair M, et al. Antithrombin III mutation database: First update. Thromb Haemostas 1993;70: 361-369
6. Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981;10:369-390
7. 0degarde OR, Abildgaard U. Antithrombin III: Critical review of assay methods. Significance of variations in health and disease. Haemostasis 1978;7:127-134
8. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin III deficiency subtypes in 4000 healthy blood donors. Thromb Haemostas 1991;65:839(Abst)
9. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: Review of 404 cases. Thromb Haemostas 1987;58: 1094(Abst)
10. Bauters A, Zawadzki C, Bura A, et al. Homozygous variant of antithrombin with lack of affinity for heparin: Management of severe thrombotic complications associated with intrauterine fetal demise. Blood Coag Fibrinolysis 1996;7:705-710
11. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981;68:1370-1373
12. Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb 1992;12:135-I45
13. Bertina RM, Broekmans AW, van der Linden IK, Mertens K. Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemostas 1982;48:l-5
14. Pabinger-Fasching I, Bertina RM, Lechner K, Niessner H, Kominger C. Protein C deficiency in two Austrian families. Thromb Haemostas 1983;50:810-813
15. Broekmans AW, Veitkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism: A study of three Dutch families. N Engl J Med 1983;309:340-344
16. Horellou MH, Conard J, Bertina RM, Samama M. Congenital protein C deficiency and thrombotic disease in nine French families. BrMed J 1984;289:1285-1287
17. Reitsma PH, Bemadi F, Doig RG, et al. Protein C deficiency: A database of mutations, 1995 update. Thromb Haemostas 1995; 73:876-889
18. Branson HE, Katz J, Marble R, Griffin JH. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet 1983;2:1165-1168
19. Seligsohn U, Berger A, Abend M, et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med 1984;310:559-562
20. Sills RH, Marlar RA, Montgomery RR, Dcshprande GN, Humbert JR. Severe homozygous protein C deficiency. J Pediatr 1984;105:409-413
21. Estellés A, Garcia-PIaza I, Dasi A, et al. Severe inherited homozygous protein C deficiency in a newborn infant. Thromb Haemostas 1984;52:53-56
22. Dreyfus M, Masterson M, David M, et al. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Haemostas 1995;21:371-381
23. Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987;317:991-996
24. Tait RC, Walker ID, Reitsma PH, ct al. Prevalence of protein C deficiency in the healthy population. Thromb Haemostas 1995;73:87-93
25. Broekmans AW, van der Linden IK, Veitkamp JJ, Bertina RM. Prevalence of isolated protein C deficiency in patients with venous thrombotic disease and in the population. Thromb Haemostas 1983;50:350(Abst)
26. Bovill EG, Bauer KA, Dickerman JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989;73:712-717
27. Allaart CF, Poort SR, Rosendaal FR, et al. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993:341:134-138
28. Koster T, Rosendaal FR, Briet E, et al. Protein C deficiency in a controlled series of unselected outpatients: An infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995;85:2756-2761
29. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc NatI Acad Sei USA 1993;90:1004-I008
30. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67
31. Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506of factor V. Lancet 1994;343:1535-1536
32. Zoller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994;343:1536-1538
33. Nicolaes GA, Tans G, Thomassen MC, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor Va R506Q by activated protein C. J Biol Chem 1995;270:21158-21166
34. Zivelin A, Griffin JH, Xu X, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997;89:397102
35. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342: 1503-1506
36. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction. N Engl J Med 1995;332:912-917
37. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:15041508
38. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997; 277:1305-1307
39. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994;84:1031-I035
40. van Boven HH, Reitsma PH, Rosendaal FR, et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemostas 1996;75:417t21
41. Zoller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995;85:35183523
42. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-1457
43. Bloemenkamp KW, Rosendaal FR, Heimerhorst FM, Biiller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contracep-tives containing a third-generation progestagen. Lancet 1995; 346:1593-1596
44. Ridker PM, Hennekens CH, Selhub J, et al. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation I997;95:1777-1782
45. Ridker PM, Miletich JP, Stampfer MJ, et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation I995;92:2800-2802
46. Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Arg506-Gin mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997;336:399-103
47. Ridker PM, Glynn RJ, Miletich JP, et al. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med 1997;126: 528-531